An FDA advisory panel has unanimously rejected Boehringer Ingelheim s application for flibanserin, a failed anti-depressant drug they proposed to use as a treatment for reduced sexual desire in women. The panel argued that the research was not robust enough to justify the risks but encouraged the company to further their research efforts.
An FDA advisory panel has unanimously rejected Boehringer Ingelheim s application for flibanserin, a failed anti-depressant drug they proposed to use as a treatment for reduced sexual desire in women. The panel argued that the research was not robust enough to justify the risks but encouraged the company to further their research efforts.
Stier believes that the decision illustrates the fact that the advisory panel has shifted to a more precautionary approach in approving new drugs. My best guess is that they don t give much weight to the seriousness of the lifestyle issue.
